Autolus Therapeutics (NASDAQ:AUTL) Announces Earnings Results, Beats Expectations By $0.02 EPS

Autolus Therapeutics (NASDAQ:AUTL) issued its quarterly earnings results on Thursday. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02, Zacks reports. The company had revenue of $26.22 million during the quarter, compared to the consensus estimate of $26.27 million. Autolus Therapeutics had a negative return on equity of 109.73% and a negative net margin of 311.98%.

Here are the key takeaways from Autolus Therapeutics’ conference call:

• Q1 revenue came in at $26.2 million, up sharply from $9.0 million a year ago, and management reiterated full-year 2026 revenue guidance of $120 million to $135 million.
• The company reported its first positive gross margin for AUCATZYL in the quarter, supported by higher volume and manufacturing/operational improvements, with margins expected to keep improving through 2026.
• Autolus said U.S. and U.K. launch momentum is building, with 73 U.S. centers active and more than 10 centers already live in the U.K.; management expects U.S. centers to exceed 80 by year-end.
• The company’s real-world data continue to support obe-cel’s profile, citing no high-grade CRS, 3% high-grade ICANS, and more than 90% overall response rate, while noting patient use is expanding into older and more complex populations.
• Management highlighted a broad pipeline for obe-cel, including pediatric ALL, lupus, lupus nephritis, progressive MS, and AL amyloidosis, with several data readouts expected in late 2026 through 2028.

Autolus Therapeutics Trading Up 2.5%

Shares of Autolus Therapeutics stock traded up $0.04 during trading on Friday, hitting $1.63. 1,482,171 shares of the stock traded hands, compared to its average volume of 1,435,440. The firm has a market cap of $433.81 million, a P/E ratio of -1.50 and a beta of 1.93. Autolus Therapeutics has a 52-week low of $1.18 and a 52-week high of $2.70. The stock’s fifty day simple moving average is $1.48 and its 200 day simple moving average is $1.52.

Hedge Funds Weigh In On Autolus Therapeutics

Institutional investors have recently made changes to their positions in the company. Marex Group plc purchased a new position in Autolus Therapeutics in the second quarter valued at about $28,000. SmartHarvest Portfolios LLC purchased a new position in Autolus Therapeutics in the fourth quarter valued at about $43,000. Caitong International Asset Management Co. Ltd purchased a new position in Autolus Therapeutics in the third quarter valued at about $46,000. Invesco Ltd. grew its stake in Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after purchasing an additional 11,381 shares during the last quarter. Finally, Federation des caisses Desjardins du Quebec acquired a new stake in shares of Autolus Therapeutics during the fourth quarter worth about $62,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on AUTL shares. Weiss Ratings downgraded Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Needham & Company LLC restated a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research report on Thursday, April 9th. Mizuho lowered their price target on Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday, March 31st. HC Wainwright lifted their target price on Autolus Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Jefferies Financial Group upgraded Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.